Medivation Inc. has licensed a
portfolio of BET bromodomain inhibitors that could have better
efficacy than the company's castration-resistant prostate cancer drug Xtandi
enzalutamide and could provide the
biotech with a new way to disrupt androgen
receptor signaling. The company got the molecules from OncoFusion Therapeutics Inc.
on the same day the startup's founders published compelling preclinical data
for inhibiting BET in the indication.1
safety, against resistance
Despite being labeled castration resistant, CRPC cells
often remain dependent on androgen signaling for
their survival, and multiple studies have shown that the transition to
castration-resistant disease is associated with reactivation of signaling
pathways that involve the AR.3,4
Lou, K.-J. SciBX 7(18); doi:10.1038/scibx.2014.510
Published online May 8, 2014
1. Asangani, I.A. et al. Nature; published online April 23, 2014;
Contact: Arul M. Chinnaiyan, University of Michigan Medical
School, Ann Arbor, Mich.
2. Wyce, A. et al. Oncotarget 4, 2419-2429
3. Attar, R.M. et al. Clin. Cancer Res. 15, 3251-3255 (2009)
4. Dutt, S.S. & Gao, A.C. Future Oncol. 5,
5. Cukier-Meisner, E. BioCentury 21(25),
A7-A9; June 24, 2013
6. Balbas, M.D. et al. eLife 2,
e00499; published online April 9, 2013; doi:10.7554/eLife.00499
7. Lou, K.-J. SciBX 6(18);
8. Li, Y. et
al. Cancer Res. 73, 483-489 (2013)
9. Arora, V.K. et al. Cell 155,
Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan
Constellation Pharmaceuticals Inc., Cambridge, Mass.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Howard Hughes Medical Institute, Chevy Chase, Md.
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
(NASDAQ:MDVN), San Francisco, Calif.
Memorial Sloan Kettering Cancer Center, New York, N.Y.
OncoFusion Therapeutics Inc., Ann Arbor, Mich.
University of Michigan, Ann Arbor, Mich.
University of Michigan Medical School, Ann Arbor, Mich.